研报掘金丨中邮证券:维持上海医药“买入”评级,看好创新业务驱动成长

格隆汇
Dec 11, 2025

格隆汇12月11日|中邮证券研报指出,上海医药商业板块稳健增长,Q3减值影响利润,看好创新业务驱动成长。公司医药商业业务继续保持增长韧性,优势区域增长态势强劲,器械大健康业务表现亮眼,新零售战略调整成效显现,CSO业务规模再创新高,创新药产品结构持续优化,供应链服务面向专业化与价值链高端延伸。2025Q1-3公司创新药业务实现销售收入407亿元,同比增长超过25%;进口总代业务实现销售收入276...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10